Dr. Moore on Challenges With Immunotherapy in Ovarian Cancer

Tackling Platinum Resistant Ovarian CancerПодробнее

Dr. Moore on Treatment for Patients With Ovarian Cancer Who Develop Resistance to PARP InhibitorsПодробнее

Dr. Moore on the Prevalence of Ovarian CancerПодробнее

Challenges With PARP Inhibitors in Ovarian CancerПодробнее

Potential for Immunotherapy in Ovarian CancerПодробнее

Dr. Moore on Research Evaluating Repeat Exposure to PARP Inhibition in Ovarian CancerПодробнее

Dr. Moore Discusses Combinations in Ovarian CancerПодробнее

Dr. Moore on Immunotherapy and PARP Combinations in BRCA-Mutated Ovarian CancerПодробнее

Dr. Moore on the Impact of SOLO-1 in Ovarian CancerПодробнее

Dr. Moore on Unanswered Questions With PARP Inhibitors in Ovarian CancerПодробнее

Dr. Moore on Early-Phase Data With Mirvetuximab Soravtansine in Ovarian CancerПодробнее

Dr. Coleman on Immunotherapy in Ovarian CancerПодробнее

Dr. Moore on the NOVA Trial for Ovarian CancerПодробнее

Immunotherapy for Endometrial Cancers: Molecular Profile- 2024 Ovarian Cancer ProgramПодробнее

Dr. Moore on the Role of Mirvetuximab Soravtansine in Ovarian CancerПодробнее

Dr. Monk Discusses Immunotherapy in Ovarian CancerПодробнее

Dr. Moore on Benefit of Mirvetuximab Soravtansine in Patients With Ovarian CancerПодробнее

Gynecologic Cancer Education: Immunotherapy & YouПодробнее

Challenges With Targeted Therapies in Ovarian CancerПодробнее

Dr. Moore on Results of the FORWARD I/GOG 3011 Trial in Ovarian CancerПодробнее